Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

16.34 +0.44 (+2.74%)
Streaming Delayed Price Updated: 11:08 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Looking Into Seres Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Preview: Seres Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Where Seres Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Why Seres Therapeutics Shares Are Surging Thursday Morning ↗
 
Via Benzinga
News headline image
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon ↗
These two biotech stocks might be significantly undervalued. 
Via The Motley Fool
News headline image
Where Seres Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Seres Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday ↗
Wells Fargo raised the price target for Molina Healthcare, Inc. (NYSE: MOH) from $282 to $290. Wells Fargo analyst Stephen Baxter maintained an Underweight rating. Molina Healthcare shares gained 7.8%... 
Via Benzinga
News headline image
Snap, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Tesla, Meta Platforms, Seres Therapeutics, Atomera, Roku: Why These 5 Stocks Are Drawing Investors' Attention Today ↗
 
Via Benzinga
News headline image
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
From Seres Therapeutics, Inc. and Nestlé Health Science
Via Business Wire
News headline image
Amazon, Microsoft, Alphabet And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023 ↗
 
Via Benzinga
News headline image
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street ↗
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts. 
Via The Motley Fool
News headline image
Stocks React To February Jobs Report: The Winners And Losers ↗
The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors. 
Via Benzinga
News headline image
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
From Seres Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.